S060 Melanoma in 2026
DESCRIPTION
This session will provide an overview of national recommendations for management of cutaneous melanoma based on current NCCN and AAD clinical practice guidelines. From the available worldwide evidence, faculty speakers will address: appropriate biopsy techniques, pathology assessment (including AJCC 8th edition staging), molecular/gene expression profiling (for biopsy, pathologic assessment and prognosis), sentinel lymph node biopsy (including risk prediction tools), surgery (including Mohs micrographic surgery and staged excision with permanent sections), nonsurgical therapy for melanoma in situ/lentigo maligna type (including topical imiquimod and radiotherapy), baseline and surveillance imaging, and adjuvant therapy for resected stage II (primary) and stage III (node-positive) melanoma.
LEARNING OBJECTIVES
Apply current AAD and NCCN cutaneous melanoma guidelines to clinical practice.
Recognize limitations and benefits of diagnostic and prognostic testing for clinical-decision making, including use of clinicopathologic nomograms and molecular testing for SLNB risk prediction and prognosis.
Describe the role of adjuvant therapy for resected stage II and stage III melanoma, including potential risks and benefits.
SCHEDULE
1:00 PM
Introduction, NCCN 2026 Key Updates
Susan M. Swetter, MD, FAAD
1:10 PM
Pathology Assessment and Reporting
1:25 PM
Tools for Bedside Diagnosis of Melanoma
Jennifer A. Stein, MD, PhD, FAAD
1:45 PM
Biopsy Techniques & Primary Surgery
Kelly Cha, MD, PhD, FAAD
2:05 PM
Prognostic Gene Expression Profiling
Douglas Grossman, MD, PhD, FAAD
2:25 PM
Mohs Surgery and Staged Excision
Christopher K. Bichakjian, MD, FAAD
2:45 PM
Alternative Therapies for Melanoma in Situ
Kelly C Nelson, MD, FAAD
3:05 PM
Sentinel Lymph Node Biopsy
Christina Angeles
3:25 PM
Adjuvant Therapy for Primary and Metastatic Melanoma
3:45 PM
Panel Discussion
DIRECTOR
Susan M. Swetter, MD, FAAD
SPEAKERS
Christina Angeles
Christopher K. Bichakjian, MD, FAAD
Kelly Cha, MD, PhD, FAAD
Douglas Grossman, MD, PhD, FAAD
Kelly C Nelson, MD, FAAD
Jennifer A. Stein, MD, PhD, FAAD
Michael Tetzlaff, MD, PhD
Hensin Tsao, MD, PhD, FAAD
DISCLOSURES
Christina Angeles
SkylineDx B.V. – Investigator(Grants/Research Funding);
Christopher K. Bichakjian, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly Cha, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Douglas Grossman, MD, PhD, FAAD
DermTech Inc. – Investigator(Fees); OrLucent, Inc. – Advisory Board(Honoraria), Investigator(Fees); Skin Analytics – Investigator(Fees);
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer A. Stein, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Susan M. Swetter, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);